Literature DB >> 15809347

The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.

Wei Zhao1, Hidenobu Soejima, Ken Higashimoto, Tetsuji Nakagawachi, Takeshi Urano, Shinichi Kudo, Shiroh Matsukura, Shuzo Matsuo, Keiichiro Joh, Tsunehiro Mukai.   

Abstract

Silencing of the O (6)-methylguanine-DNA methyltransferase (MGMT) gene, a key to DNA repair, is involved in carcinogenesis. Recent studies have focused on DNA hypermethylation of the promoter CpG island. However, cases showing silencing with DNA hypomethylation certainly exist, and the mechanism involved is not elucidated. To clarify this mechanism, we examined the dynamics of DNA methylation, histone acetylation, histone methylation, and binding of methyl-CpG binding proteins at the MGMT promoter region using four MGMT negative cell lines with various extents of DNA methylation. Histone H3K9 di-methylation (H3me2K9), not tri-methylation, and MeCP2 binding were commonly seen in all MGMT negative cell lines regardless of DNA methylation status. 5Aza-dC, but not TSA, restored gene expression, accompanied by a decrease in H3me2K9 and MeCP2 binding. In SaOS2 cells with the most hypomethylated CpG island, 5Aza-dC decreased H3me2K9 and MeCP2 binding with no effect on DNA methylation or histone acetylation. H3me2K9 and DNA methylation were restricted to in and around the island, indicating that epigenetic modification at the promoter CpG island is critical. We conclude that H3me2K9 and MeCP2 binding are common and more essential for MGMT silencing than DNA hypermethylation or histone deacetylation. The epigenetic mechanism leading to silent heterochromatin at the promoter CpG island may be the same in different types of cancer irrespective of the extent of DNA methylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809347     DOI: 10.1093/jb/mvi048

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  17 in total

1.  MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.

Authors:  Er Nie; Xin Jin; Weining Wu; Tianfu Yu; Xu Zhou; Zhumei Shi; Junxia Zhang; Ning Liu; Yongping You
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

2.  MECP2 impairs neuronal structure by regulating KIBRA.

Authors:  Alison A Williams; Robin White; Ashley Siniard; Jason Corneveaux; Matt Huentelman; Carsten Duch
Journal:  Neurobiol Dis       Date:  2016-03-22       Impact factor: 5.996

3.  Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-cultured with feeder cells.

Authors:  B W Darbro; K M Lee; N K Nguyen; F E Domann; A J Klingelhutz
Journal:  Oncogene       Date:  2006-06-12       Impact factor: 9.867

4.  Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.

Authors:  Chih-Yi Hsu; Hsiang-Ling Ho; Shih-Chieh Lin; Yi-Chun Chang-Chien; Ming-Hsiung Chen; Sanford Ping-Chuan Hsu; Yu-Shu Yen; Wan-You Guo; Donald Ming-Tak Ho
Journal:  J Neurooncol       Date:  2015-01-10       Impact factor: 4.130

5.  Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Ann C Mladek; Brett L Carlson; Mark A Schroeder; Jenny L Pokorny; Ling Cen; Paul A Decker; Wenting Wu; Gwen A Lomberk; Shiv K Gupta; Raul A Urrutia; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

6.  Histone modifiers, YY1 and p300, regulate the expression of cartilage-specific gene, chondromodulin-I, in mesenchymal stem cells.

Authors:  Tomoki Aoyama; Takeshi Okamoto; Kenichi Fukiage; Seiji Otsuka; Moritoshi Furu; Kinya Ito; Yonghui Jin; Michiko Ueda; Satoshi Nagayama; Tomitaka Nakayama; Takashi Nakamura; Junya Toguchida
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

7.  Genome-wide profiling of histone H3 lysine 9 acetylation and dimethylation in Arabidopsis reveals correlation between multiple histone marks and gene expression.

Authors:  Junli Zhou; Xiangfeng Wang; Kun He; Jean-Benoit F Charron; Axel A Elling; Xing Wang Deng
Journal:  Plant Mol Biol       Date:  2010-04       Impact factor: 4.076

8.  Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Authors:  Sibille Everhard; Jörg Tost; Hafida El Abdalaoui; Emmanuelle Crinière; Florence Busato; Yannick Marie; Ivo G Gut; Marc Sanson; Karima Mokhtari; Florence Laigle-Donadey; Khê Hoang-Xuan; Jean-Yves Delattre; Joëlle Thillet
Journal:  Neuro Oncol       Date:  2009-02-17       Impact factor: 12.300

Review 9.  MGMT testing--the challenges for biomarker-based glioma treatment.

Authors:  Wolfgang Wick; Michael Weller; Martin van den Bent; Marc Sanson; Markus Weiler; Andreas von Deimling; Christoph Plass; Monika Hegi; Michael Platten; Guido Reifenberger
Journal:  Nat Rev Neurol       Date:  2014-06-10       Impact factor: 42.937

10.  Structure-specific binding of MeCP2 to four-way junction DNA through its methyl CpG-binding domain.

Authors:  Teca Calcagno Galvão; Jean O Thomas
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.